CTKB - Cytek Biosciences, Inc. Stock Price, Fair Value and News

6.09USD-0.09 (-1.46%)Delayed

Market Summary

USD6.09-0.09

Delayed

-1.46%

CTKB Alerts

1 major insider sales recently.

Losses in recent quarter

CTKB Stock Price

View Fullscreen

CTKB RSI Chart

CTKB Valuation

Market Cap

799.5M

Price/Earnings (Trailing)

-69.46

Price/Sales (Trailing)

3.98

EV/EBITDA

-89.06

Price/Free Cashflow

478.71

CTKB Price/Sales (Trailing)

CTKB Profitability

EBT Margin

-7.80%

Return on Equity

-2.93%

Return on Assets

-2.34%

Free Cashflow Yield

0.21%

CTKB Fundamentals

CTKB Revenue

Revenue (TTM)

200.8M

Rev. Growth (Yr)

20.96%

Rev. Growth (Qtr)

-22.97%

CTKB Earnings

Earnings (TTM)

-11.5M

Earnings Growth (Yr)

9.37%

Earnings Growth (Qtr)

-212.1%

Breaking Down CTKB Revenue

Last 7 days

-3.3%

Last 30 days

2.9%

Last 90 days

-28.4%

Trailing 12 Months

-9.0%

How does CTKB drawdown profile look like?

CTKB Financial Health

Current Ratio

6.99

CTKB Investor Care

Buy Backs (1Y)

3.24%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	200.8M	0	0	0
2023	166.1M	175.6M	183.1M	193.0M
2022	138.7M	148.5M	154.6M	164.0M
2021	101.6M	110.4M	119.2M	128.0M
2020	0	0	0	92.8M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cytek Biosciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 19, 2024	yan ming	sold	-117,400	5.87	-20,000	chief technology officer
Apr 09, 2024	yan ming	sold	-13,304	7.00211	-1,900	chief technology officer
Mar 20, 2024	busque philippe	acquired	-	-	5,464	svp, global sales and services
Mar 20, 2024	busque philippe	sold (taxes)	-14,264	6.7	-2,129	svp, global sales and services
Mar 19, 2024	yan ming	sold	-134,200	6.71	-20,000	chief technology officer
Mar 18, 2024	yan ming	sold	-135,400	6.77	-20,000	chief technology officer
Mar 11, 2024	poirson allen	sold (taxes)	-9,393	7.22	-1,301	svp bus. and corp. dev.
Mar 11, 2024	poirson allen	acquired	-	-	3,338	svp bus. and corp. dev.
Mar 11, 2024	barnett valerie	acquired	-	-	4,908	chief legal officer
Mar 11, 2024	jeanmonod patrik	sold (taxes)	-13,804	7.22	-1,912	chief financial officer

Which funds bought or sold CTKB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-76.88	-1,508,060	309,077	-%
May 16, 2024	COMERICA BANK	reduced	-9.44	-137,503	274,566	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-10.94	-387,265	736,100	-%
May 16, 2024	Grandeur Peak Global Advisors, LLC	unchanged	-	-79,846	222,309	0.02%
May 15, 2024	UBS ASSET MANAGEMENT AMERICAS LLC	added	0.82	-289,898	832,919	-%
May 15, 2024	WELLINGTON MANAGEMENT GROUP LLP	added	4.93	-2,684,420	9,091,850	-%
May 15, 2024	BARCLAYS PLC	reduced	-43.69	-1,012,000	715,000	-%
May 15, 2024	DARK FOREST CAPITAL MANAGEMENT LP	new	-	76,407	76,407	0.01%
May 15, 2024	MORGAN STANLEY	added	0.88	-1,965,720	5,660,030	-%
May 15, 2024	BROWN CAPITAL MANAGEMENT LLC	added	0.05	-28,921,200	80,667,700	1.43%

Are Funds Buying or Selling CTKB?

Are funds buying CTKB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CTKB

No. of Funds

Unveiling Cytek Biosciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 22, 2024	ra capital management, l.p.	5.2%	6,809,404	SC 13G
Feb 14, 2024	brown capital management llc	8.86%	12,016,325	SC 13G
Feb 14, 2024	yan ming	4.7%	6,203,867	SC 13G/A
Feb 14, 2024	jiang wenbin	4.3%	5,702,130	SC 13G/A
Feb 14, 2024	hhlr advisors, ltd.	4.9%	6,657,030	SC 13G/A
Feb 13, 2024	vanguard group inc	8.77%	11,890,700	SC 13G/A
Jan 23, 2024	blackrock inc.	13.1%	17,779,753	SC 13G/A
Sep 19, 2023	ra capital management, l.p.	4.99%	6,809,404	SC 13D/A
May 05, 2023	blackrock inc.	10.9%	14,835,215	SC 13G/A
Feb 14, 2023	hhlr advisors, ltd.	6.4%	8,684,530	SC 13G/A

Recent SEC filings of Cytek Biosciences, Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	4	Insider Trading
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Apr 23, 2024	4	Insider Trading
Apr 11, 2024	4	Insider Trading
Apr 09, 2024	144	Notice of Insider Sale Intent
Mar 21, 2024	4	Insider Trading

Peers (Alternatives to Cytek Biosciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.13%	32.26%	-0.09	0.28	5.77%	8.23%

Cytek Biosciences, Inc. News

Latest updates

Cytek Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	-23.0%	44,860	58,234	48,000	49,693	37,088	48,336	40,477	40,159	35,064	38,894	34,376	30,408	24,272	24,684	25,096	19,136
Gross Profit	-30.4%	23,013	33,048	27,178	28,162	21,038	29,374	26,862	24,561	20,177	23,636	21,277	19,745	14,486	-	15,616	8,270
Operating Expenses	1.7%	33,747	33,185	33,598	37,289	33,200	29,290	25,502	25,452	22,534	22,319	18,380	15,934	13,354	-	8,905	8,488
S&GA Expenses	8.5%	12,543	11,561	12,076	14,367	11,145	9,029	8,810	8,431	6,960	8,304	6,553	5,576	4,277	-	3,838	3,059
R&D Expenses	-9.9%	9,796	10,870	11,171	12,136	9,974	9,747	8,650	8,436	8,025	7,076	6,078	6,194	5,094	-	3,376	2,916
EBITDA Margin	10.4%	-0.04*	-0.04*	-0.04*	-0.02*	0.01*	0.04*	0.02*	0.02*	0.05*	0.07*	0.13*	0.14*	0.15*	-	-	-
Interest Expenses	11.9%	441	394	595	409	673	687	649	647	590	492	441	433	375	-	2.00	1.00
Income Taxes	-101.1%	-2,800	-1,392	2,271	-2,207	-2,233	396	224	-699	-1,145	1,609	655	597	50.00	-	357	-7,919
Earnings Before Taxes	-318.8%	-8,993	4,111	-4,185	-6,595	-9,040	4,114	1,850	-1,401	-3,303	444	2,075	3,267	152	-	6,897	192
EBT Margin	4.2%	-0.08*	-0.08*	-0.09*	-0.06*	-0.03*	0.01*	-0.02*	-0.01*	0.02*	0.05*	0.12*	0.13*	0.14*	-	-	-
Net Income	-212.1%	-6,169	5,503	-6,456	-4,388	-6,807	3,598	1,626	-598	-2,021	-1,165	1,420	2,670	102	5,599	6,540	8,111
Net Income Margin	8.9%	-0.06*	-0.06*	-0.08*	-0.03*	-0.01*	0.02*	-0.01*	-0.02*	0.01*	0.02*	0.08*	0.14*	0.20*	-	-	-
Free Cashflow	-57.7%	3,390	8,012	-5,569	-4,163	2,353	-337	-8,614	-10,768	-2,260	4,152	-147	-5,165	1,426	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-0.5%	492	494	519	525	525	519	499	493	486	463	454	230	220
Current Assets	-0.9%	389	392	422	425	426	454	444	443	439	432	440	217	209
Cash Equivalents	1.1%	169	167	164	132	129	297	342	350	363	365	377	160	166
Inventory	-10.1%	55.00	61.00	67.00	66.00	70.00	48.00	49.00	45.00	38.00	32.00	28.00	27.00	23.00
Net PPE	-0.9%	18.00	18.00	17.00	16.00	16.00	14.00	8.00	7.00	7.00	6.00	5.00	4.00	2.00
Goodwill	0%	16.00	16.00	16.00	19.00	19.00	10.00	10.00	10.00	10.00	10.00	0.00	0.00	0.00
Liabilities	-1.9%	99.00	101	104	101	101	94.00	83.00	82.00	78.00	58.00	51.00	47.00	42.00
Current Liabilities	-1.2%	56.00	56.00	59.00	54.00	57.00	49.00	41.00	42.00	43.00	33.00	30.00	28.00	27.00
Shareholder's Equity	-0.1%	393	393	416	424	423	426	417	411	407	405	403	-	-16.03
Retained Earnings	-21.1%	-35.35	-29.18	-34.68	-28.22	-23.84	-17.03	-20.56	-22.22	-21.63	-19.61	-18.41	-19.83	-22.61
Additional Paid-In Capital	1.4%	429	423	452	454	448	443	437	433	428	424	421	8.00	6.00
Shares Outstanding	0.4%	131	131	136	136	136	135	135	134	134	77.00	58.00	32.00	-
Float	-	-	-	-	1,030	-	1,300	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-58.4%	3,957	9,512	-4,239	-2,850	2,858	6,193	-7,504	-9,440	-1,480	5,448	1,161	-3,914	1,935	-	-	-
Share Based Compensation	-0.5%	5,640	5,669	5,758	5,922	4,699	4,465	4,359	3,934	3,837	3,008	2,455	667	456	-	-	-
Cashflow From Investing	-119.8%	-5,754	29,066	43,124	2,790	-168,874	-51,064	-1,150	-2,915	-780	-18,296	-1,308	-1,251	-138	-	-	-
Cashflow From Financing	104.8%	1,613	-33,754	-8,274	216	-	3,850	155	1,144	364	17.00	217,078	-3,723	187	-	-	-
Buy Backs	-100.0%	-	34,600	8,428	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CTKB Income Statement

2024-03-31

Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue, net:
Total revenue, net	$ 44,860	$ 37,088
Cost of sales:
Total cost of sales	21,847	16,050
Gross profit	23,013	21,038
Operating expenses:
Research and development	9,796	9,974
Sales and marketing	12,543	11,145
General and administrative	11,408	12,081
Total operating expenses	33,747	33,200
Loss from operations	(10,734)	(12,162)
Other income (expense):
Interest expense	(441)	(673)
Interest income	1,359	2,143
Other income, net	823	1,652
Total other income, net	1,741	3,122
Loss before income taxes	(8,993)	(9,040)
Benefit from income taxes	(2,824)	(2,233)
Net loss	(6,169)	(6,807)
Net loss, basic	(6,169)	(6,807)
Net loss, diluted	$ (6,169)	$ (6,807)
Net loss per share, basic (in dollars per share)	$ (0.05)	$ (0.05)
Net loss per share, diluted (in dollars per share)	$ (0.05)	$ (0.05)
Weighted-average shares used in calculating net loss per share, basic (in shares)	130,920,971	135,489,194
Weighted-average shares used in calculating net loss per share, diluted (in shares)	130,920,971	135,489,194
Comprehensive loss:
Net loss	$ (6,169)	$ (6,807)
Foreign currency translation adjustment, net of tax	(244)	(42)
Unrealized (loss) gain on marketable securities	(35)	152
Net comprehensive loss	(6,448)	(6,697)
Product
Revenue, net:
Total revenue, net	34,122	31,172
Cost of sales:
Total cost of sales	16,746	12,677
Service
Revenue, net:
Total revenue, net	10,738	5,916
Cost of sales:
Total cost of sales	$ 5,101	$ 3,373

CTKB Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 168,788	$ 167,299
Restricted cash	353	331
Marketable securities	101,298	95,111
Trade accounts receivable, net	50,306	55,928
Inventories	54,742	60,877
Prepaid expenses and other current assets	13,160	12,514
Total current assets	388,647	392,060
Deferred income tax assets, noncurrent	32,708	30,487
Property and equipment, net	18,247	18,405
Operating lease right-of-use assets	9,949	10,853
Goodwill	16,183	16,183
Intangible assets, net	22,252	23,084
Other noncurrent assets	4,081	3,385
Total assets	492,067	494,457
Current liabilities:
Trade accounts payable	3,725	3,032
Legal settlement liability, current	2,550	2,561
Accrued expenses	18,054	20,035
Other current liabilities	8,228	7,903
Deferred revenue, current	23,009	22,695
Total current liabilities	55,566	56,226
Legal settlement liability, noncurrent	16,722	16,477
Deferred revenue, noncurrent	15,164	15,132
Operating lease liability, noncurrent	8,697	9,479
Long term debt	1,477	1,648
Other noncurrent liabilities	1,827	2,431
Total liabilities	99,453	101,393
Commitments and contingencies (Note 18)
Stockholders’ equity:
Common stock, $0.001 par value; 1,000,000,000 authorized shares as of March 31, 2024 and December 31, 2023, respectively; 131,254,181 and 130,714,906 issued and outstanding shares as of March 31, 2024 and December 31, 2023, respectively.	131	131
Additional paid-in capital	429,384	423,386
Accumulated deficit	(35,347)	(29,178)
Accumulated other comprehensive loss	(1,554)	(1,275)
Total stockholders’ equity	392,614	393,064
Total liabilities and stockholders’ equity	$ 492,067	$ 494,457

About Cytek Biosciences, Inc.

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

CEO	Dr. Wenbin Jiang Ph.D.
WEBSITE	https://cytekbio.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	699

Cytek Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Cytek Biosciences, Inc.? What does CTKB stand for in stocks?

CTKB is the stock ticker symbol of Cytek Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cytek Biosciences, Inc. (CTKB)?

As of Fri May 17 2024, market cap of Cytek Biosciences, Inc. is 799.45 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CTKB stock?

You can check CTKB's fair value in chart for subscribers.

What is the fair value of CTKB stock?

You can check CTKB's fair value in chart for subscribers. The fair value of Cytek Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cytek Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CTKB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cytek Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether CTKB is over valued or under valued. Whether Cytek Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Cytek Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CTKB.

What is Cytek Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CTKB's PE ratio (Price to Earnings) is -69.46 and Price to Sales (PS) ratio is 3.98. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CTKB PE ratio will change depending on the future growth rate expectations of investors.